How effective is bisphosphonate treatment for preventing bone fractures after liver transplantation?
Hay
J Eileen
JE
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. jhay@mayo.edu
D015502:Absorptiometry, Photon; D000328:Adult; D015415:Biomarkers; D015992:Body Mass Index; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology; D002119:Calcium Carbonate / Q000494:pharmacology / Q000627:therapeutic use; D002762:Cholecalciferol / Q000494:pharmacology / Q000627:therapeutic use; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D002762:Cholecalciferol; D000077211:Zoledronic Acid; D002119:Calcium Carbonate